IP Library Granted Patent US 7,608,579
Granted Patent B2
US 7,608,579 · App. 11/008,093 · Granted Oct 27, 2009

Lung volume reduction using glue compositions

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,608,579
App. No.
11/008,093
Granted
Oct 27, 2009
Kind
B2
Abstract

The present invention relates to methods and compositions for sealing localized regions of damaged lung tissue to reduce overall lung volume. The glue compositions provide a glue featuring an adhering moiety coupled to one or more other moieties including, for example, a cross-linkable moiety and/or one other adhering moiety. The methods and compositions of the invention find use, for example, in treating pulmonary conditions, such as emphysema.

Claims (29)

1. A method of reducing lung volume in a lung of a subject in need thereof comprising:

providing a glue composition comprising a first adhering moiety connected via an amide bond linkage to a first site on a chemical linker, and a second adhering moiety which is connected via an amide bond to a second site on said chemical linker, wherein the chemical linker comprises a functional group selected from the group consisting of a carboxyl group and an amine group, and wherein said first and second adhering moieties adhere to different sites bearing elastase in a lung, and are independently selected from the group consisting of a) alpha-1 antitrypsin, b) elafin, and c) serpin;

administering an effective amount of said glue composition to a localized region of damaged lung tissue of said subject;

adhering said first adhering moiety to a first site bearing elastase in said localized region of damaged lung tissue of said subject;

collapsing a first portion or all of said lung of said subject wherein said first portion comprises said localized region of damaged lung tissue;

adhering said second adhering moiety to a second site bearing elastase in said damaged lung tissue; and

re-inflating a second portion of the lung of said subject wherein said second portion does not comprise said damaged lung tissue, thereby reducing said lung volume.

2. The method as recited in claim 1 wherein said lung tissue comprises epithelial lining fluid.

3. The method as recited in claim 1 wherein said administering delivers said glue composition to a deep lung region.

4. The method as recited in claim 1 wherein said method is performed with prior identification of said damaged lung tissue.

5. The method as recited in claim 1 wherein said method does not damage epithelial cells within lung tissue.

6. The method as recited in claim 1 wherein said method damages epithelial cells within lung tissue by use of a sclerosing agent.

7. The method as recited in claim 6 wherein said sclerosing agent is at least one compound selected from doxycycline, bleomycin, minocycline, doxorubicin, cisplatin+cytarabine, mitoxantrone, Corynebacterium Parvum , streptokinase, and urokinase.

8. The method as recited in claim 1 wherein said glue composition does not comprise a polysaccharide or a carbohydrate moiety.

9. The method as recited in claim 1 wherein said composition does not comprise a mutant plasminogen activator-inhibitor type 1.

10. The method as recited in claim 1 wherein said elastase is neutrophil elastase.

11. The method as recited in claim 1 wherein said glue composition is less than 10 microns.

12. The method as recited in claim 1 wherein said glue composition is less than 5 microns.

13. The method as recited in claim 1 wherein said glue composition is less than 1 micron.

14. The method as recited in claim 1 wherein said administering is carried out via inhalation.

15. The method as recited in claim 14 wherein said inhalation is carried out via the mouth.

16. The method as recited in claim 1 wherein said administering is carried out via trans-thoracic administration.

17. The method as recited in claim 1 wherein said administering is carried out by placing a bronchoscope in a bronchi of a deep lung region.

18. The method as recited in claim 17 , further comprising placing a catheter through said bronchoscope to reach a subsegmental bronchi.

19. The method as recited in claim 18 wherein said catheter comprises an expandable balloon-like structure.

20. The method as recited in claim 1 wherein said collapsing comprises use of negative pressure within the lung of said subject.

21. The method as recited in claim 1 wherein said collapsing comprises use of positive pressure not from the lung of said subject.

22. The method as recited in claim 1 wherein said subject is suffering from a pulmonary condition.

23. The method as recited in claim 22 wherein said pulmonary condition is emphysema or chronic obstructive pulmonary disease.

Assignments (3)
CHANGE OF NAME Recorded Feb 13, 2020
From: PNEUMRX, INC.
To: PNEUMRX LLC
Reel/Frame 051925/0350 →
NUNC PRO TUNC ASSIGNMENT Recorded Feb 13, 2020
From: PNEUMRX LLC
To: EKOS LLC
Reel/Frame 051925/0675 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 8, 2005
From: GONG, GLEN; DIECK, RONALD
To: PNEUMRX, INC.
Reel/Frame 016364/0453 →